Inhaled Corticosteroid Market Report 2024 (Global Edition)

Global Inhaled Corticosteroid Market Report 2024 Market Size Split by Steroid Inhaler Type (Beclomethasone Dipropionate, Budesonide, Fluticasone Inhaler Powder, Mometasone), by Application (Asthma, CO...

Inhaled Corticosteroid Market Report Description

We have various report editions of Inhaled Corticosteroid Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Inhaled Corticosteroid Market

Key players deploy strategic initiatives such as product innovations, partnerships, and mergers. Companies prioritize R&D to introduce cutting-edge reagents, ensuring a competitive edge. Robust distribution networks and adherence to quality standards amplify market presence, fostering an environment where agility and innovation define industry leaders.

Top Companies Market Share in Inhaled Corticosteroid Industry: (In no particular order of Rank)

• Sumitomo
• Pfizer
• Novartis
• Merck
• Sanofi
• Johnson and Johnson
• GSK
• AstraZeneca
• Teijin
• Glaxo's Advair
• Amgen
• Kos Pharmaceutical
• Teva Pharmaceutical.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Inhaled Corticosteroid Market

Which Region Dominates the Inhaled Corticosteroid Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue. Growing knowledge of treatment choices, the high prevalence of respiratory disorders like COPD and asthma, and improvements in inhalation technology are driving growth in North America's Inhaled Corticosteroid (ICS) market. The market for inhalation devices and ICS drugs is being driven by the region's healthcare industry, which is focused on lowering healthcare costs and improving patient outcomes.

Which Region is Expanding at the Fastest CAGR?

The European region is witnessing an increase in the sales of reagents. Europe's inhaled corticosteroid (ICS) market is expanding due to rising knowledge of effective management choices, rising prevalence of respiratory disorders like COPD and asthma, and developments in inhaler technology. Furthermore, the region's strong healthcare system and advantageous reimbursement practices encourage market growth and present chances for pharmaceutical businesses to launch cutting-edge ICS products.

The current report Scope analyzes Inhaled Corticosteroid Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Inhaled Corticosteroid Market

According to Cognitive Market Research, the global Inhaled Corticosteroid market size was estimated at USD 945.2 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 378.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.4% from 2024 to 2031. The market for inhaled corticosteroids (ICS) is expanding rapidly in North America due to the high incidence of respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD) in the area. The growing use of combination treatments, which pair ICS with other medicines including long-acting beta agonists (LABAs) for improved efficacy in treating respiratory symptoms, is a key factor driving this growth. As a result of developments in inhalation technology and a rising understanding of the significance of treating respiratory disorders, healthcare practitioners in North America are increasingly prescribing inhaled corticosteroids (ICS) with a focus on improving patient outcomes and disease management. It is anticipated that this pattern will hold true, propelling additional ICS market expansion in the area.

Country Analysis

• According to Cognitive Market Research, the US had a major share in the Inhaled Corticosteroid market with a market size of USD 298.31 million in 2024 and is projected to grow at a CAGR of 3.2% during the forecast period. The demand is amplified by the nation's the high prevalence of respiratory conditions like asthma and COPD. 
• The Canada Inhaled Corticosteroid market had a market share of USD 45.37 million in 2024 and is projected to grow at a CAGR of 4.2% during the forecast period. Canada's rising increasing healthcare expenditure.
• The Mexico Inhaled Corticosteroid market is projected to witness growth at a CAGR of 3.9% during the forecast period with a market size of USD 34.41 million in 2024.

Europe Inhaled Corticosteroid Market

According to Cognitive Market Research, with a market value of USD 945.2 million in 2024 and projected to expand at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031. Europe accounted for a share of over 30% of the global market size of USD 283.56 million. The market for inhaled corticosteroids (ICS) is expanding steadily in Europe since the continent has a higher than average incidence of respiratory conditions such asthma and chronic obstructive pulmonary disease (COPD). The growing need for biologic therapy and customized medicine, which supplement ICS treatments for severe asthma sufferers, is a major factor propelling this expansion. Healthcare systems in Europe are adopting novel treatment strategies that include ICS drugs with the goal of improving patient care and cutting costs. Regulations intended to provide access to efficient respiratory treatments also contribute to the market's expansion. The European ICS industry is well-positioned for further growth and innovation to satisfy changing patient demands as respiratory health becomes more and more important to legislators and healthcare professionals.

• The United Kingdom Inhaled Corticosteroid market had a market share of USD 47.64  million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. In the UK, Inhaled Corticosteroid sales witness an upswing due to the nation's  advancements in inhalation technology. 
• The France Inhaled Corticosteroid market is projected to witness growth at a CAGR of 2.9% during the forecast period with a market size of USD 26.09 million in 2024.
• According to Cognitive Market Research, the Germany Inhaled Corticosteroid market size was valued at USD 56.14 million in 2024 and is projected to grow at a CAGR of 3.9% during the forecast period. In Germany, Inhaled Corticosteroid sales surge due to the nation's the emphasis on personalized medicine and biologic therapies complements. 
• The Italy Inhaled Corticosteroid market is projected to witness growth at a CAGR of 3.1% during the forecast period with a market size of USD 24.39 million in 2024.
• The Russia Inhaled Corticosteroid market is projected to witness growth at a CAGR of 2.7% during the forecast period with a market size of USD 43.95 million in 2024.
• The Spain Inhaled Corticosteroid market is projected to witness growth at a CAGR of 2.8% during the forecast period with a market size of USD 23.25 million in 2024.
• The Luxembourg Inhaled Corticosteroid market is projected to witness growth at a CAGR of 3.8% during the forecast period with a market size of USD 8.79 million in 2024.
• The Portugal Inhaled Corticosteroid market is projected to witness growth at a CAGR of 3.5% during the forecast period with a market size of USD 5.95 million in 2024.
• The Greece Inhaled Corticosteroid market is projected to witness growth at a CAGR of 4.0% during the forecast period with a market size of USD 3.40 million in 2024.
• Rest of Europe Inhaled Corticosteroid market is projected to witness growth at a CAGR of 2.4% during the forecast period with a market size of USD 43.95 million in 2024.

Asia Pacific Inhaled Corticosteroid Market

According to Cognitive Market Research, the global Inhaled Corticosteroid market size was estimated at USD 945.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 217.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031. The market for inhaled corticosteroids (ICS) is growing quickly in the Asia Pacific area as a result of rising healthcare costs and the rising incidence of respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). The increasing use of combination therapy, which combine ICS with long-acting beta agonists (LABAs) or other drugs to improve therapeutic efficacy, is a key factor fueling this development. Healthcare professionals in Asia Pacific are increasingly including ICS drugs in treatment regimens with the goal of enhancing respiratory health outcomes and attending to patients' unmet medical needs. It is anticipated that this trend will continue, helped by improvements in the healthcare system and rising public awareness of the significance of controlling respiratory illnesses.

• According to Cognitive Market Research, the China Inhaled Corticosteroid market size was valued at USD 97.83 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. Inhaled Corticosteroid sales surge in China due to the nation's rapid expansion in the rapid urbanization.
• The Japan Inhaled Corticosteroid market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD 30.00 million in 2024.
• The India Inhaled Corticosteroid market had a market share of USD 26.09 million in 2024 and is projected to grow at a CAGR of 9.0% during the forecast period. The demand is augmented by India's increasing pollution levels.
• The South Korea Inhaled Corticosteroid market is projected to witness growth at a CAGR of 6.3% during the forecast period with a market size of USD 21.74 million in 2024.
• The Australia Inhaled Corticosteroid market is projected to witness growth at a CAGR of 6.9% during the forecast period with a market size of USD 11.30 million in 2024.
• The South East Asia Inhaled Corticosteroid market is projected to witness growth at a CAGR of 8.2% during the forecast period with a market size of USD 15.0 million in 2024.
• The Rest of Asia Pacific Inhaled Corticosteroid market is projected to witness growth at a CAGR of 7.0% during the forecast period with a market size of USD 15.44 million in 2024.

South America Inhaled Corticosteroid Market

According to Cognitive Market Research, the global Inhaled Corticosteroid market size was estimated at USD 945.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 47.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031. The market for inhaled corticosteroids (ICS) is expanding steadily in Latin America because to an increase in the incidence of respiratory conditions such asthma and chronic obstructive pulmonary disease (COPD). The rising need for accessible and reasonably priced respiratory medicines, especially from underprivileged populations in rural regions, is a significant factor driving this growth. Healthcare professionals in Latin America are increasingly prescribing ICS drugs as part of comprehensive respiratory disease management programs, with an emphasis on solving unmet medical needs and enhancing the region's healthcare infrastructure. Initiatives to improve respiratory health outcomes throughout the region and increase access to necessary drugs are projected to sustain this trend.

• According to Cognitive Market Research, the Brazil Inhaled Corticosteroid market size was valued at USD 20.23 million in 2024 and is projected to grow at a CAGR of 5.2% during the forecast period. Inhaled Corticosteroid sales flourish in Brazil due to the nation's a growing aging population.
• The Argentina Inhaled Corticosteroid market had a market share of USD 7.94 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. The demand is augmented by Argentina's commitment to leading to a higher prevalence of respiratory diseases. 
• The Colombia Inhaled Corticosteroid market is projected to witness growth at a CAGR of 4.4% during the forecast period with a market size of USD 4.21 million in 2024.
• The Peru Inhaled Corticosteroid market is projected to witness growth at a CAGR of 4.8% during the forecast period with a market size of USD 3.88 million in 2024.
• The Chile Inhaled Corticosteroid market is projected to witness growth at a CAGR of 4.9% during the forecast period with a market size of USD 3.40 million in 2024.
• The Rest of Latin America Inhaled Corticosteroid market is projected to witness growth at a CAGR of 3.7% during the forecast period with a market size of USD 7.61 million in 2024.

Middle East and Africa Inhaled Corticosteroid Market

According to Cognitive Market Research, the global Inhaled Corticosteroid market size was estimated at USD 945.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 18.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031. The market for inhaled corticosteroids (ICS) is expanding in the Middle East and Africa because to the increased occurrence of respiratory conditions such asthma and chronic obstructive pulmonary disease (COPD). The growing emphasis on illness management techniques and preventative healthcare practices is a key factor driving this expansion. Healthcare professionals in the area are providing ICS drugs to patients more frequently as a result of a growing understanding of the significance of reducing respiratory symptoms and enhancing quality of life. The Middle East & Africa's ICS market is expected to continue growing as a result of initiatives to improve healthcare infrastructure and provide access to necessary pharmaceuticals.

• According to Cognitive Market Research, the GCC Countries Inhaled Corticosteroid market size was valued at USD 8.09 million in 2024 and is projected to grow at a CAGR of 5.7% during the forecast period. Inhaled Corticosteroid sales flourish in the GCC Countries due to the region's The government's focus on improving healthcare infrastructure and access to essential medications.
• The Egypt Inhaled Corticosteroid market is projected to witness growth at a CAGR of 5.2% during the forecast period with a market size of USD 1.98 million in 2024.
• The South Africa Inhaled Corticosteroid market is projected to witness growth at a CAGR of 5.9% during the forecast period with a market size of USD 2.99 million in 2024. Inhaled Corticosteroid sales flourish in the South Africa due to the region's strategic investments in healthcare research and advancements.
• The Turkey Inhaled Corticosteroid market is projected to witness growth at a CAGR of 4.4% during the forecast period with a market size of USD 1.63 million in 2024.
• The Nigeria Inhaled Corticosteroid market is projected to witness growth at a CAGR of 4.0% during the forecast period with a market size of USD 1.98 million in 2024.
• The Rest of MEA Inhaled Corticosteroid market is projected to witness growth at a CAGR of 3.9% during the forecast period with a market size of USD 2.23 million in 2024.

Inhaled Corticosteroid Market Analysis

Inhaled Corticosteroid Market Segment Analysis

According to Cognitive Market Research, Beclomethasone Dipropionate held the major market share over the forecast period. The market for inhaled corticosteroids (ICS) is expanding because of the effectiveness of budesonide, a powerful ICS used to treat various respiratory ailments, including COPD and asthma. More and more medical professionals are prescribing budesonide due to its anti-inflammatory qualities and good safety record. Budesonide's accessibility and patient adherence are further improved by its availability in a variety of formulations and delivery methods, which propels the market's growth.

Budesonide is the fastest-growing category over the forecast period. The market for inhaled corticosteroids (ICS) is expanding due in large part to the increasing incidence of asthma throughout the globe. The need for efficient maintenance treatments like inhaled corticosteroids (ICS) is growing because asthma is still a chronic respiratory disease that affects millions of people worldwide. As awareness of the significance of regulating asthma symptoms and averting exacerbations grows, the ICS industry is seeing notable

• Beclomethasone Dipropionate
• Budesonide
• Fluticasone Inhaler Powder
• Mometasone

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Inhaled Corticosteroid Industry. Request a Free Sample PDF!

Inhaled Corticosteroid Market Type Segment Analysis 

According to Cognitive Market Research, Asthma holds a prominent market share. Renowned for their versatility, these reagents are the linchpin in chromatographic techniques, supporting a spectrum of Steroid Inhaler Types from pharmaceuticals to environmental analysis. The consistent demand for reliable and efficient separation methods positions chromatography reagents as market leaders, their prevalence reflective of the scientific community's unwavering reliance on precise analytical tools.

COPD (Chronic Obstructive Pulmonary Disease) is the fastest-growing category over the forecast period. Globally, the incidence of Chronic Obstructive Pulmonary Disease (COPD) is rising, which is driving the market for inhaled corticosteroids (ICS). Since COPD is a leading source of morbidity and death, there is an increasing need for maintenance medications that effectively manage symptoms and lessen exacerbations, such as ICS. The ICS market is expected to continue growing as a result of the growing attention and knowledge.

• Asthma
• COPD (Chronic Obstructive Pulmonary Disease)
• Others

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Inhaled Corticosteroid Dosage form Segment Analysis

According to Cognitive Market Research, Aerosol held the major market share over the forecast period. Aerosol inhalation devices improve the efficacy of inhaled corticosteroids (ICS) for respiratory disorders such as asthma and COPD by providing easy and effective drug administration straight to the lungs. The demand for aerosol-based ICS solutions is rising, which is helping to expand the market. This is due to developments in aerosol technology as well as patients' growing preference for inhalers that are easy to use.

Liquid is the fastest-growing category over the forecast period. Improved inhaling technique and accurate dosage administration are two benefits of liquid-based inhaled cordial formulations. The demand for liquid ICS solutions is rising among patients and healthcare professionals as a result of developments in patient-centered drug delivery methods and formulation technology. This is driving the growth of the ICS market.

• Aerosol Liquid
• Powder

Inhaled Corticosteroid End-User Segment Analysis

According to Cognitive Market Research, Hospitals and Clinics held the major market share over the forecast period. ICS drugs are in higher demand as medical facilities work to control respiratory ailments, including COPD and asthma, and to provide better respiratory care. In order to address patient needs, hospitals and clinics function as the main places of care where medical experts prescribe and administer ICS therapy, which propels market expansion.

Academic and Research Institutes is the fastest-growing category over the forecast period. By developing new drugs and managing respiratory illnesses, academic and research institutions are driving the Inhaled Corticosteroid (ICS) industry. Focusing on researching the safety and effectiveness of ICS drugs, these organizations promote innovation and offer evidence-based guidelines for their application. Research and development activities are further propelled by collaborations between academia, industry, and healthcare institutions, which in turn expands the market for ICS.

• Hospitals and Clinics
• Academic and Research Institutes
• Respiratory Care Center

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion